This funding follows Novellia’s work powering research for the world’s largest pharmaceutical companies, the signing of multiple seven-figure contracts, and the recent launch of its patient-facing mobile app. Novellia, the world’s only real-world data company powered entirely by patient-donated information for medical research, today announced an $18 million Series A round led by Spark Capital, with participation from Khosla Ventures, Acrew Capital, Bling Capital, and TMV. The round brings Novellia’s total funding to $28 million. Building on this momentum, Novellia is launching its patient-facing mobile app—an extension of its award-winning online platform—that enables individuals to securely access their full health history. Researchers have long relied on real-world data to understand how treatments perform beyond the confines of clinical trials. Yet the contemporary data landscape is controlled by third-party brokers who piece together incomplete datasets drawn from insurance claims and hospital records. The outcome is a system that burns through more than $50 billion each year yet still excludes the most vital source of truth: the patient himself. “Behind every patient lies a fragmented, incomplete record of their life,” said Shashi Shankar, Co-Founder and CEO of Novellia. I saw it firsthand: first during my grandfather’s battle with cancer, and later in my pharmaceutical career, where we developed treatments without ever grasping the complete picture. The system let down both patients and researchers simultaneously. Novellia is transforming the entire industry by placing the patient at its core.
